Results 61 to 70 of about 3,194,674 (312)

Venn diagram of adverse event definitions.

, 2018
Venn diagram of adverse event definitions.
Becky Skidmore (182146), Fatemeh Yazdi (103976), Lisa Burry (8599), Claire Butler (685145), Dianna Wolfe (3494750), David Moher (17203), Salmaan Kanji (3433226), Leila Esmaeilisaraji (5848661), Mona Hersi (811564), Candyce Hamel (811566), Andrew Beck (389972), Brian Hutton (543037)   +11 more
core   +1 more source

Establishing an Apheresis Medicine Program in a Resource‐Constrained Setting: A 5‐Year Experience From Lagos, Nigeria

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Establishing a comprehensive apheresis medicine program in a resource‐constrained setting presents significant structural, financial, and logistical challenges. Despite the growing clinical importance of apheresis services globally, published experience from sub‐Saharan Africa remains sparse.
Folasade Adelekan‐Popoola, Shakirat Gold‐Olufadi, Olufunto Olufela Kalejaiye, Abdullateef Ogala, Rasheed A. Balogun   +4 more
wiley   +1 more source

Adverse event profile differences between maribavir and valganciclovir: findings from the FDA adverse event reporting system

Frontiers in Pharmacology
BackgroundMaribavir and valganciclovir are pharmacotherapeutic options utilized in the management of cytomegalovirus (CMV) infection post-transplantation.
Haolin Teng, Shengnan Zhang, Jinyu Yu, Faping Li   +3 more
doaj   +1 more source

Pharmaceutical systematics: Description and preliminary investigation of an alternative method for structuring drug information

INNOVATIONS in Pharmacy, 2011
Objectives: To identify the 30 most common adverse drug events or reactions (ADE/ADRs) within the top 200 medications: (1) by raw incidence, (2) weighted by prescription volume, (3) and weighted by retail dollars.
Mary E. Kiersma, Aleda M. H. Chen, Kristin R. Villa, Brian M. Shepler, Matthew M. Murawski   +4 more
doaj   +1 more source

Nature of adverse event previously observed.

, 2019
Nature of adverse event previously observed.
Oliver Ombeva Malande (6335906), Rachel Nakatugga Afaayo (6335909), Elizabeth Ayebare (5225339), Edison Arwanire Mworozi (6335921), Kisakye Annet (6335912), Andrew Munyalo Musyoki (6335924), Bongomin Bodo (5119280), Deogratias Munube (3534944), Andrew Bakainaga (6335915), Sam Njunwamukama (6335918)   +9 more
core   +1 more source

Comparative Evaluation of Hemodiafiltration, Hemoperfusion, and Standard Hemodialysis on Efficacy, Inflammatory Control, Dialysis Adequacy, and Safety in End‐Stage Renal Disease: A Prospective Observational Study

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Chronic micro‐inflammation in patients with end‐stage renal disease (ESRD) is a significant driver of cardiovascular complications and diminished quality of life. While standard hemodialysis (SHD) effectively manages small‐molecule clearance, its ability to remove medium‐to‐large uremic toxins—the primary catalysts of systemic ...
Hongwei Zuo, Weisi Dai, Jie Mao, Mei Ye, Xingshan Lu, Xiaocui Zhang   +5 more
wiley   +1 more source

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database

Frontiers in Pharmacology
BackgroundFaricimab is the first and only bispecific antibody approved by the U.S. Food and Drug Administration (FDA) for intravitreal injection. Given its increasingly widespread use in retinal vascular diseases, understanding its adverse events (AEs ...
Chang-Zhu He, Qin Qiu, Song-Jie Lu, Fu-Li Xue, Jun-Qiao Liu, Yu He   +5 more
doaj   +1 more source

Safety of Daprodustat for the Treatment of Chronic Kidney Disease Anemia: Final Analysis of a Multicenter Postmarketing Surveillance Study in Japan

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Introduction This final analysis of a multicenter, prospective postmarketing surveillance study evaluated the safety of daprodustat in patients with chronic kidney disease anemia in routine clinical practice in Japan. Methods Patients who initiated daprodustat between September 2020 and July 2022 were registered.
Tadao Akizawa, Kyomi Kanaya, Kiyomi Aizawa, Masanori Onoki, Hirofumi Ozeki, Kazuko Suzuki, Ai Hayashi, Tomohiko Asamura   +7 more
wiley   +1 more source

Hemin coupled protein biomimetic nanozymes combining confinement effects for sensitive chemiluminescence immunoassay

ChemPhysMater
Nanozymes offer superior stability and resistance to deactivation while mimicking the catalytic activity of natural enzymes, thereby expanding their applications across various fields.
Tong Jiang, Yanan Lou, Jin Wang, Huan Wang, Yuyang Li, Hongmin Ma   +5 more
doaj   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source